Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323501 | 0.82 | HTR6 (0.52) | ROCK1MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL4324839 | 0.81 | ROCK1 (0.50) | ROCK1MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL15957895 | 0.81 | TP53 (0.55) | MAPTMAPK1TDP1L3MBTL1GAA | |
| SCHEMBL13957837 | 0.81 | RHEB (0.44) | RHEBROCK1MAPTMAPK1TDP1 | |
| SCHEMBL18049242 | 0.80 | HTR6 (0.67) | ROCK1MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL7958584 | 0.80 | HTR6 (0.50) | ROCK1MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL23956093 | 0.79 | HTR2C (0.56) | ROCK1MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL23408944 | 0.79 | RHEB (0.47) | RHEBROCK1L3MBTL1HTR6GAA | |
| SCHEMBL4328875 | 0.79 | HTR6 (0.52) | ROCK1MAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL21393149 | 0.79 | NOTUM (0.51) | ROCK1MAPTMAPK1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117164498-A | Method for synthesizing cyclic monoterpene indole compound | 苏州大学 | 2023-12-05 | — | — | CN | disclosed |
| CN-111909074-A | Method for preparing indole compound by air oxidation catalyzed by N-hydroxyphthalimide | 宁波大学 | 2020-11-10 | — | — | CN | disclosed |
| EP-2691393-B1 | NOVEL BICYCLIC PYRIDINONES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9067934-B2 | Bicyclic pyridinones | PFIZER INC. (US) | 2015-06-30 | — | — | US | disclosed |
| CN-102459223-B | 5-pyridin-3-yl-1, 3-dihydro-indol-2-one derivatives and their use as aldosterone synthase and/or CYP11B1 modulators | NOVARTIS AG | 2014-11-05 | — | — | CN | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8778972-B2 | 5-pyridin-3-yl-1, 3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1 | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-7528164-B2 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528164-B2 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528164-B2 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| CN-100349887-C | Substituted 4-aryl-4H-pyrrolo [2, 3-H ] chromenes and analogs, pharmaceutical compositions and uses thereof | CYTOVIA INC (US) | 2007-11-21 | — | — | CN | disclosed |
| EP-1509515-A4 | SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| CN-1668609-A | Substituted 4-aryl-4H-pyrrolo[2,3-H]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA INC (US) | 2005-09-14 | — | — | CN | disclosed |
| EP-1509515-A2 | SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097806-A2 | SUBSTITUTED 4-ARYL-4H-PYRROLO[2,3-H]CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275175-A1 | ORGANIC COMPOUNDS | CYP11B2, CYP11B1, SLCO1B1 | RHEB 3215/4885ROCK1 1645/4885MAPT 1619/4885 |
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP4, CASP2 | RHEB 806/4885ROCK1 618/4885MAPT 4700/4885 |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | CYP11B1, HSD11B1, CYP11B2 | RHEB 2181/4885ROCK1 130/4885MAPT 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.